Pyxis Oncology: Speculative Buy Opportunity With Multiple Catalysts Ahead

Stock Information for Pyxis Oncology Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Pyxis Oncology Inc.

Pyxis Oncology Reports First Quarter 2025 Financial Results and Provides Business Update
Pyxis Oncology to Participate in Two Upcoming Investor Conferences
Pyxis Oncology Presents Promising Preclinical Results Providing Proof of Mechanism of Micvotabart Pelidotin, the First-in-Concept Extracellular-Targeting ADC
Pyxis Oncology to Participate in the Stifel 2025 Virtual Targeted Oncology Forum
Pyxis Oncology to Present New Preclinical Data Supporting Development of First-In-Concept ADC Targeting EDB+FN in Tumor Microenvironment at AACR 2025
Pyxis Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
Pyxis Oncology to Participate at the Leerink Partners Global Healthcare Conference
Pyxis Oncology Granted FDA Fast Track Designation for PYX-201 Monotherapy in Patients with Recurrent or Metastatic Head and Neck Cancer

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.